Screening for nasopharyngeal cancer in residents
Part of Cancer, Ear, nose & throat, Infections, Mouth & dental clinical trials.
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a resident of the study area.
- You must be between 30 and 69 years old.
- You must be able to cooperate with screening and follow-up visits.
- You must not have severe heart, liver, or kidney disease.
- You must not have a history of cancer.
- You must not have a severe autoimmune disease or immunodeficiency.
- If you are female, you must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This study looks at the molecular features of nasopharyngeal carcinoma to find better ways to predict treatment success and identify new targets for therapy. It’s for people already treated at Union Hospital in Wuhan.
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.